ArticleBMC chemistry2026
Spectrofluorimetric quantification of terconazole in pharmaceutical creams with comprehensive sustainability evaluation.
Article in BMC chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Terconazole is an effective antifungal drug with a broad spectrum of activity against many types of fungi. In the study, a spectrofluorimetric method was developed for the quantification of terconazole. Eosin Y, an efficient fluorescence probe, was used in the developed work. The developed method is based on forming a non-fluorescent association complex between terconazole and eosin Y, which quenches eosin Y's inherent fluorescence intensity at both excitation and emission spectra. This quenching effect is highly correlated with the concentration of terconazole, with a linear range of 0.15-1.2 µg/mL. Furthermore, Stern-Volmer analysis was carried out to study the quenching fluorescence strength of eosin Y by terconazole. Moreover, the developed method exhibits an LOD of 0.041 µg/mL and a LOQ of 0.125 µg/mL. Moreover, the recommended method was verified in accordance with ICH guidelines. In addition, with respectable recovery values, the established procedures were successfully applied to the analysis of terconazole in vaginal cream dosage forms. Furthermore, the greenness of the entire proposed project was assessed using the following assessment tools: MoGAPI, Complex MoGAPI, MoGSA, BAGI, and RAPI. The green profiles provided outstanding evidence of the greenness and environmental friendliness of the proposed approach.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.